Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16370603 | 0.77 | ALDH1A1 (0.32) | ALDH1A1DGAT1 | |
| SCHEMBL29797022 | 0.74 | DGAT1 (0.38) | ALDH1A1DGAT1CNR2GAA | |
| SCHEMBL7071375 | 0.71 | DGAT1 (0.35) | ALDH1A1DGAT1CNR2 | |
| SCHEMBL31105040 | 0.71 | DGAT1 (0.35) | ALDH1A1DGAT1CNR2 | |
| SCHEMBL18116696 | 0.70 | DGAT1 (0.33) | ALDH1A1DGAT1MEN1KMT2AGAA | |
| SCHEMBL3322447 | 0.69 | — | — | |
| SCHEMBL171079 | 0.68 | PTPN1 (0.38) | ALDH1A1CNR2 | |
| SCHEMBL14946218 | 0.68 | ALDH1A1 (0.33) | ALDH1A1DGAT1GAA | |
| SCHEMBL16370688 | 0.68 | MMP8 (0.39) | DGAT1 | |
| SCHEMBL8165907 | 0.67 | DGAT1 (0.39) | ALDH1A1DGAT1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122181-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-17 | — | — | US | disclosed |
| EP-4408837-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE IL-17 INHIBITOR COMPOUNDS | JANSSEN Pharmaceutica NV (BE) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023049885-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122181-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | IL17A, IL23R, IL2 | ALDH1A1 240/4885DGAT1 4482/4885MEN1 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.